PHR1246
非诺贝特
Pharmaceutical Secondary Standard; Certified Reference Material
别名:
2- [4-（4-氯苯甲酰）苯氧基]-2-甲基丙酸异丙酯
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H21ClO4
化学文摘社编号:
分子量:
360.83
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
256-376-3
MDL number:
产品名称
非诺贝特, Pharmaceutical Secondary Standard; Certified Reference Material
InChI key
YMTINGFKWWXKFG-UHFFFAOYSA-N
InChI
1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3
SMILES string
CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2
grade
certified reference material
pharmaceutical secondary standard
agency
traceable to Ph. Eur. F0048000
traceable to USP 1269447
API family
fenofibrate
CofA
current certificate can be downloaded
technique(s)
HPLC: suitable
gas chromatography (GC): suitable
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Quality Level
Gene Information
human ... PPARA(5465)
正在寻找类似产品? 访问 产品对比指南
Analysis Note
These secondary standards offer multi-traceability to the US and EP primary standards, where they are available.
Application
Fenofibrate may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations by various chromatography and spectrophotometry techniques.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
General description
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Fenofibrate is a third-generation fibric acid derivative which is widely employed for the treatment of atherogenic dyslipidemia, hypertriglyceridemia, mixed dyslipidemia and hypercholesterolemia.
Fenofibrate is a third-generation fibric acid derivative which is widely employed for the treatment of atherogenic dyslipidemia, hypertriglyceridemia, mixed dyslipidemia and hypercholesterolemia.
Other Notes
Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.
This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
To see an example of a Certificate of Analysis for this material enter LRAC0257 in the slot below. This is an example certificate only and may not be the lot that you receive.
signalword
Warning
hcodes
pcodes
Hazard Classifications
STOT RE 2 Oral
target_organs
Liver
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Simultaneous Estimation of Rosuvastatin Calcium and Fenofibrate in Bulk and in Tablet Dosage Form by UV-Spectrophotometry and RP-HPLC
Karunakaran A, et al.
Stamford Journal of Pharmaceutical Sciences, 4(1), 58-63 (2011)
Electrochemical studies and square-wave voltammetric determination of fenofibrate in pharmaceutical formulations
Yardimci C and Ozaltin N
Analytical and Bioanalytical Chemistry, 378(2), 495-498 (2004)
Estimation of Atorvastatin Calcium and Fenofibrate in Tablets by Derivative Spectrophotometry and Liquid Chromatography
Nakarani NV, et al.
Journal of AOAC (Association of Official Analytical Chemists) International, 90(3), 700-705 (2007)
Stanley M H Chan et al.
Diabetes, 62(6), 2095-2105 (2013-01-26)
Endoplasmic reticulum (ER) stress is suggested to cause hepatic insulin resistance by increasing de novo lipogenesis (DNL) and directly interfering with insulin signaling through the activation of the c-Jun N-terminal kinase (JNK) and IκB kinase (IKK) pathway. The current study
Cordula Stillhart et al.
The Journal of pharmacy and pharmacology, 65(2), 181-192 (2013-01-03)
To advance in vitro screening of surfactant/co-solvent formulations in early development by considering drug supersaturation and the mechanism of solubilization upon aqueous dilution. Two surfactant/co-solvent model systems were studied at practically relevant aqueous dilution ratios. Precipitation of the model drug
相关内容
默克Supelco®标准物质不断推出或更新满足海关及法规要求的标准物质。每年我们约有上百种的新CRM或标准物质上市，在此我们尽可能多的列出满足海关及法规要求的标准物质。
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持